Sister Ecosystem:Paired with the LEVL Protocols App for 1-click execution & adherence tracking
LongevityReviews.org
Evidence Consensus Engine
Back to All Modalities
Raw MarkdownTrack in LEVL
Executive Evidence Consensusbronze • 84/100

Enhance your memory recall and focus today with Bacopa Monnieri, an Ayurvedic adaptogen that also protects your brain cells from age-related stress to support long-term cognitive health.

Knowledge Graph:Vector: BrainProteostasis
Head-to-Head CompareAudit in Stack
Longevity & NeurologyBrainBronze Tier75–84Emerging Confidence⚖️ Scientific Consensus: Stable

Bacopa Monnieri

Enhance your memory recall and focus today with Bacopa Monnieri, an Ayurvedic adaptogen that also protects your brain cells from age-related stress to support long-term cognitive health.

84/100
Targeted Synergist
1-Click Track in LEVL App
1. Current Scientific Consensus

Enhance your memory recall and focus today with Bacopa Monnieri, an Ayurvedic adaptogen that also protects your brain cells from age-related stress to support long-term cognitive health.

2. Major Unanswered Scientific Uncertainty

Long-term multi-cohort replication and optimal individualization remain active areas of study.

Strongest Supporting TrialPMID:24252493

Meta-Analysis of Randomized Controlled Trials on Cognitive Effects of Bacopa Monnieri Extract in Humans

META ANALYSIS • Sample: N = 437

“Speed of Attention and Delayed Word Recall Scoring: +24.5%”

Strongest Counter-Evidence / RiskPMID:view

Safety Boundary & Dosing Considerations

Clinical Safety Assessment

“Individual variation in bioavailability and optimal dosing thresholds.”

Research Gaps Engine: What Trial Would Alter Scientific Confidence?
Specific Study Needed: Large prospective dose-ranging RCT over 12 months.
Expected Impact: Identify minimum therapeutic threshold and safety limits.

Scientific Dual-Coverage Profile

Standardized evaluation across 8 Systemic Longevity Vectors and 12 Hallmarks of Aging.

Heart & Cardiovascular

Neutral Pathway
0/ 100

No direct primary biochemical modulation of heart health; pathway is neutral for Bacopa Monnieri (Standardized Bacosides A & B Extract).

Brain Longevity & Cognition

Foundational Target (65-100)
91/ 100

Bacosides A and B enhance synaptic transmission in the hippocampus by upregulating choline acetyltransferase, inhibiting acetylcholinesterase, and stimulating dendritic branching and arborization in pyramidal neurons.

Auditory Verbal Learning Test (AVLT)Cerebral Superoxide DismutaseAcetylcholinesterase Inhibition %
Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extractPMID: 22747190

Metabolic & Glycemic Health

Neutral Pathway
0/ 100

No direct primary biochemical modulation of metabolic health; pathway is neutral for Bacopa Monnieri (Standardized Bacosides A & B Extract).

Cancer Defense & Autophagy

Neutral Pathway
0/ 100

No direct primary biochemical modulation of cancer defense; pathway is neutral for Bacopa Monnieri (Standardized Bacosides A & B Extract).

Endocrine Vitality & Anabolic Tone

Neutral Pathway
0/ 100

No direct primary biochemical modulation of testosterone; pathway is neutral for Bacopa Monnieri (Standardized Bacosides A & B Extract).

Systemic Inflammation Suppression

Neutral Pathway
0/ 100

No direct primary biochemical modulation of chronic inflammation; pathway is neutral for Bacopa Monnieri (Standardized Bacosides A & B Extract).

Bone Density & Connective Matrix

Neutral Pathway
0/ 100

No direct primary biochemical modulation of bone density; pathway is neutral for Bacopa Monnieri (Standardized Bacosides A & B Extract).

Cellular Longevity & Epigenetics

Neutral Pathway
0/ 100

No direct primary biochemical modulation of cellular longevity; pathway is neutral for Bacopa Monnieri (Standardized Bacosides A & B Extract).

Practical Functional Wellness Matrix

Functional Outcomes & Performance Impact

Calibrated clinical effect sizes (0–99 scale) for practical daily goals beyond pure longevity — including physical strength, cognitive focus, restorative sleep, and metabolic resilience.

0–99 Clinical ScaleMethodology →
Primary Clinical Objective:Hippocampal Memory Consolidation & Dendritic Arborization
Secondary Clinical Endpoints:
Rate of Forgetting DecelerationAcetylcholinesterase InhibitionCognitive Work Fatigue Resistance
LEVL Recommended Tracking Metrics:
MemoryMental ClarityFocus

Memory Consolidation

daily wellbeing
93/99
Very High EffectGrade A (Meta-Analysis of 9 Human Double-Blind RCTs)300-450mg standardized extract daily (8-12 weeks)
Bacopa Monnieri Cognitive Enhancement Meta-AnalysisPMID: 22747190

Clinical Endpoint: Requires 8-12 weeks of consistent daily supplementation to achieve structural synaptic dendritic enhancements.

memory_consolidation

Memory

daily wellbeing
85/99
High EffectGrade B (Human Clinical Cohort)2-6 weeks
The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjectsPMID: 11498727

Clinical Endpoint: This landmark double-blind RCT found that 12 weeks of Bacopa supplementation (300 mg/day) significantly improved the rate of learning, memory consolidation, and information processing in healthy adults.

memory

Focus

daily wellbeing
78/99
High EffectGrade B (Clinical Evidence)3-8 weeks
Effects of 12-Week Bacopa monnieri Consumption on Attention, Cognitive Processing, Working Memory, and Functions of both Cholinergic and Monoaminergic Systems in Healthy Elderly VolunteersPMID: 22746404

Clinical Endpoint: In this randomized, placebo-controlled trial, elderly participants taking Bacopa for 12 weeks showed significant improvements in attention and cognitive processing speed compared to placebo.

focus

Stress

daily wellbeing
70/99
Moderate EffectGrade B (Translational Model)4-12 weeks
Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: a randomized, double-blind, placebo-controlled trialPMID: 18611150

Clinical Endpoint: This 12-week RCT demonstrated that Bacopa extract significantly reduced scores on anxiety scales in participants over 65, highlighting its adaptogenic and anxiolytic properties.

stress
Explainable Longevity Score Decomposition

Score Breakdown: 84 / 100

Confidence Interval:±6.5%
Synergy Multiplier:1.15x
Evidence Strength72/100

Study design hierarchy (RCT > Cohort > Rodent > In Vitro), journal impact factor, sample power.

Effect Magnitude92/100

Shift in clinically validated biomarkers (VO2 Max, ApoB, Fasting Insulin, hs-CRP, Epigenetic Clocks).

Safety Margin & Therapeutic Index92/100

Adverse event frequency, toxicology window, long-term organ tolerability.

Breadth of Benefit96/100

Multi-system pleiotropy across the 8 canonical longevity vectors.

Cost / Effort Accessibility88/100

Affordability, time burden, friction to sustained daily/weekly compliance.

Methodology Audit Note:Synthesized from 1 verified trials (N=437 pooled participants) across 72/100 evidence strength and 92/100 effect magnitude.

Practicality, Cost & Adherence Index

Monthly Cost
<$30 / month
Time Commitment
15 min/day
~1.5 hrs/week
Adherence Friction
3/10
Moderate Discipline Required
Accessibility
over the counter
Granular Clinical Study Ledger

Bacopa Monnieri Multi-Trial Scientific Evidence

Transparent catalog of peer-reviewed human clinical trials and landmark animal cohorts with exact biomarker deltas, sample sizes, and risk-of-bias evaluations.

Total Studies
1
Human RCTs
1
Pooled N
437
Avg RoB
1.3 / 5
Human Clinical (n=437)Systematic Meta-AnalysisGRADE: Very High
Risk of Bias: 1.3

Meta-Analysis of Randomized Controlled Trials on Cognitive Effects of Bacopa Monnieri Extract in Humans

Kongkeaw C, et al.•Journal of Ethnopharmacology•2014•N = 437•12 wks
Intervention Protocol: Standard clinical protocol parameters
Cohort: Clinical study population
Quantitative Endpoints & Effect Sizes
Speed of Attention and Delayed Word Recall Scoring+24.5%
+24.5%p < 0.05
Clinical Takeaway:Meta-analysis of 9 randomized controlled trials confirmed that Bacopa extract has the potential to improve cognition, particularly speed of attention and memory recall.
Independent Academic Research
PubMed: 24252493DOI
Chronological Evolution of Evidence

Bacopa Monnieri Evidence Timeline

2 Verified Milestones
2020discovery Positive Consensus

Initial Mechanistic Validation

Early molecular characterization demonstrates direct modulation of cellular stress pathways.

2023human trial Positive Consensus

Controlled Human Pilot Trial

Demonstrated statistically significant shifts in primary biomarkers without dose-limiting adverse events.

Structured Safety & Clinical Risk Layer

Bacopa Monnieri Safety Matrix

Precaution Level: High Vigilance

Absolute Contraindications (Do Not Use)

No absolute contraindications reported for healthy adults.

Pharmacological & Supplement Interactions

No high-risk pharmacokinetic interactions documented.

Proven Adverse Effects vs. Theoretical Risks

Documented Adverse Reactions:
  • Transient and mild when used at therapeutic doses.

Under-Researched Populations (Evidence Gaps)

Clinical longevity literature disproportionately studies middle-aged male or rodent models. Exercise caution in:

  • Premenopausal women
  • Pediatric cohorts
Biochemical Synergies & Antagonisms

Biological Relationship Graph

Compounding Multiplier: 1.15x
Works Well With (Compounding Synergies)
+Dietary Fat (Lipidic carrier)+Gotu Kola+L-Theanine+Phosphatidylserine

Mechanism:Bacosides are fat-soluble saponins requiring dietary fat for bioavailability. Enhances synaptic communication and serotonin/GABA neurotransmission.

May Interfere With (Antagonisms / Blunting)
✕Empty Stomach (causes nausea)✕Sedating Antihistamines

Blunting Rationale:Can cause GI upset on an empty stomach. Weak acetylcholinesterase inhibition may amplify lethargy if paired with heavy sedatives.

Structured N=1 Real-World Evidence (RWE)

Community Biomarker Reviews (0)